Mirum Pharmaceuticals Completes Enrollment in AZURE-1 and AZURE-4 Studies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy MIRM?
Mirum Pharmaceuticals announced completion of enrollment in the Phase 3 AZURE-1 study and completion of screening in the Phase 3 AZURE-4 study, both evaluating brelovitug for the treatment of chronic hepatitis delta virus. Achievement of these milestones confirms the expected timing of topline 24-week data in the second half of 2026. AZURE-1 and AZURE-4 together will form the basis of Mirum's U.S. BLA submission for brelovitug, which has received Breakthrough Therapy designation from the FDA for the treatment of chronic HDV infection. Topline data from AZURE-1 and AZURE-4 are expected in 2H 2026, with a potential BLA submission and launch in the U.S. in 2027.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MIRM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MIRM
Wall Street analysts forecast MIRM stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 90.930
Low
81.00
Averages
102.33
High
140.00
Current: 90.930
Low
81.00
Averages
102.33
High
140.00
About MIRM
Mirum Pharmaceuticals, Inc. is a rare disease company with a global footprint of approved products and a pipeline of investigational medicines. Its commercial portfolio includes LIVMARLI (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM (cholic acid) for bile-acid synthesis disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis (CTX). Its clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS). Livmarli is an orally administered, minimally absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with ALGS in the United States and other countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mirum Pharmaceuticals Reports Strong Q4 2025 Earnings and 2026 Guidance
- Strong Sales Performance: Mirum Pharmaceuticals reported Q4 2025 net product sales of $149 million, a 50% increase from $99 million in the prior year, with total annual sales reaching $521 million, exceeding guidance and reflecting robust performance in Alagille syndrome and PFIC markets.
- 2026 Sales Outlook: Management projects net product sales for 2026 to be between $630 million and $650 million, indicating confidence in market demand for LIVMARLI and the new drug Brelovitug, which is expected to drive further growth in the rare disease sector.
- Increased R&D Investment: The company anticipates a rise in R&D expenses in 2026, primarily for the Brelovitug clinical program and manufacturing validation, with management emphasizing that these investments will prepare the company for future BLA submissions and maintain its competitive edge.
- Cash Flow and Financial Health: By the end of 2025, Mirum had $391 million in cash and cash equivalents, achieving positive cash flow from operations, demonstrating financial stability that supports business expansion and new product development.
See More
Mirum (MIRM) Q4 2025 Earnings Call Transcript
See More
Mirum Pharmaceuticals Reports Q4 Revenue Growth of 49.8%
- Significant Revenue Growth: Mirum Pharmaceuticals reported Q4 revenue of $148.9 million, reflecting a 49.8% year-over-year increase, surpassing market expectations by $7.12 million, which underscores the company's strong performance in market demand and product promotion, solidifying its position in the biopharmaceutical sector.
- Net Loss Reported: Despite the substantial revenue growth, Mirum recorded a net loss of $5.73 million in Q4, indicating ongoing investments in R&D and market expansion, which are expected to lay the groundwork for long-term growth.
- Funding Initiative: Mirum plans to raise $68.5 million through a private placement with TCGX, with the funds aimed at accelerating product development and market outreach, enhancing the company's competitiveness in the highly competitive pharmaceutical market.
- Future Outlook: At the upcoming J.P. Morgan Healthcare Conference, Mirum will present its positive outlook on VOLIXIBAT PSC treatment data, anticipating greater market potential by 2026, which is expected to further bolster investor confidence in the company.
See More
Penn Capital Increases Stake in ACM Research, Inc.
- New Investment Dynamics: Penn Capital Management established a new position in ACM Research during Q4 2025, acquiring 435,843 shares, with a quarter-end value increase of $17.21 million, reflecting strong confidence in the semiconductor equipment market.
- Asset Allocation Shift: This new position accounts for 1.37% of Penn Capital's 13F reportable assets under management, indicating a strategic focus on the semiconductor industry, particularly in the context of AI and advanced chip manufacturing.
- Outstanding Stock Performance: As of February 6, 2026, ACM Research shares were priced at $62.48, up 171.5% over the past year, outperforming the S&P 500 by 157.6 percentage points, showcasing market recognition of its growth potential.
- Industry Outlook Analysis: ACM Research specializes in providing advanced cleaning and plating equipment for semiconductor manufacturing, and with the surge in AI processor demand, the company’s revenue from the Chinese market is significant, facing dual challenges of self-sufficiency and export controls.
See More
Penn Capital Initiates Position in ACM Research with $17.21 Million Investment
- New Investment Position: Penn Capital initiated a position in ACM Research during Q4 2025 by purchasing 435,843 shares for an estimated $17.21 million, reflecting confidence in the semiconductor sector.
- Value Appreciation: As of December 31, 2025, the position's quarter-end value stood at $17.21 million, indicating a positive impact from both the share purchase and price movements, showcasing market recognition of ACM Research.
- Strong Market Performance: As of February 6, 2026, ACM Research shares were priced at $62.48, representing a 171.5% increase over the previous year, generating 157.6 percentage points of alpha compared to the S&P 500, highlighting its robust performance in the semiconductor equipment market.
- Promising Industry Outlook: ACM Research focuses on advanced wafer cleaning and plating equipment, and with the rising demand for AI processors, its products are becoming increasingly vital in semiconductor manufacturing, positioning the company for greater market share amidst China's push for semiconductor self-sufficiency.
See More
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Mirum Pharmaceuticals will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026, with a fireside chat at 1:10 p.m. ET, aimed at enhancing investor understanding of the company's strategic direction.
- Multiple Conference Engagements: The company will also attend The Citizens Life Sciences Conference and Barclays 28th Annual Global Healthcare Conference on March 10, 2026, showcasing its leadership in the rare disease sector and further enhancing investor interaction.
- Live Webcast Accessibility: All fireside chats will be webcast live via Mirum's corporate website, ensuring transparency of information and improving communication efficiency between the company and its investors.
- Product Portfolio and Pipeline: Mirum's commercial portfolio includes LIVMARLI® for Alagille syndrome and PFIC, along with CHOLBAM® for bile-acid synthesis disorders, demonstrating the company's deep expertise and market potential in rare disease treatments.
See More
Mirum Pharmaceuticals Reports Strong Q4 2025 Earnings and 2026 Guidance
- Strong Sales Performance: Mirum Pharmaceuticals reported Q4 2025 net product sales of $149 million, a 50% increase from $99 million in the prior year, with total annual sales reaching $521 million, exceeding guidance and reflecting robust performance in Alagille syndrome and PFIC markets.
- 2026 Sales Outlook: Management projects net product sales for 2026 to be between $630 million and $650 million, indicating confidence in market demand for LIVMARLI and the new drug Brelovitug, which is expected to drive further growth in the rare disease sector.
- Increased R&D Investment: The company anticipates a rise in R&D expenses in 2026, primarily for the Brelovitug clinical program and manufacturing validation, with management emphasizing that these investments will prepare the company for future BLA submissions and maintain its competitive edge.
- Cash Flow and Financial Health: By the end of 2025, Mirum had $391 million in cash and cash equivalents, achieving positive cash flow from operations, demonstrating financial stability that supports business expansion and new product development.
See More
Mirum (MIRM) Q4 2025 Earnings Call Transcript
See More
Mirum Pharmaceuticals Reports Q4 Revenue Growth of 49.8%
- Significant Revenue Growth: Mirum Pharmaceuticals reported Q4 revenue of $148.9 million, reflecting a 49.8% year-over-year increase, surpassing market expectations by $7.12 million, which underscores the company's strong performance in market demand and product promotion, solidifying its position in the biopharmaceutical sector.
- Net Loss Reported: Despite the substantial revenue growth, Mirum recorded a net loss of $5.73 million in Q4, indicating ongoing investments in R&D and market expansion, which are expected to lay the groundwork for long-term growth.
- Funding Initiative: Mirum plans to raise $68.5 million through a private placement with TCGX, with the funds aimed at accelerating product development and market outreach, enhancing the company's competitiveness in the highly competitive pharmaceutical market.
- Future Outlook: At the upcoming J.P. Morgan Healthcare Conference, Mirum will present its positive outlook on VOLIXIBAT PSC treatment data, anticipating greater market potential by 2026, which is expected to further bolster investor confidence in the company.
See More
Penn Capital Increases Stake in ACM Research, Inc.
- New Investment Dynamics: Penn Capital Management established a new position in ACM Research during Q4 2025, acquiring 435,843 shares, with a quarter-end value increase of $17.21 million, reflecting strong confidence in the semiconductor equipment market.
- Asset Allocation Shift: This new position accounts for 1.37% of Penn Capital's 13F reportable assets under management, indicating a strategic focus on the semiconductor industry, particularly in the context of AI and advanced chip manufacturing.
- Outstanding Stock Performance: As of February 6, 2026, ACM Research shares were priced at $62.48, up 171.5% over the past year, outperforming the S&P 500 by 157.6 percentage points, showcasing market recognition of its growth potential.
- Industry Outlook Analysis: ACM Research specializes in providing advanced cleaning and plating equipment for semiconductor manufacturing, and with the surge in AI processor demand, the company’s revenue from the Chinese market is significant, facing dual challenges of self-sufficiency and export controls.
See More
Penn Capital Initiates Position in ACM Research with $17.21 Million Investment
- New Investment Position: Penn Capital initiated a position in ACM Research during Q4 2025 by purchasing 435,843 shares for an estimated $17.21 million, reflecting confidence in the semiconductor sector.
- Value Appreciation: As of December 31, 2025, the position's quarter-end value stood at $17.21 million, indicating a positive impact from both the share purchase and price movements, showcasing market recognition of ACM Research.
- Strong Market Performance: As of February 6, 2026, ACM Research shares were priced at $62.48, representing a 171.5% increase over the previous year, generating 157.6 percentage points of alpha compared to the S&P 500, highlighting its robust performance in the semiconductor equipment market.
- Promising Industry Outlook: ACM Research focuses on advanced wafer cleaning and plating equipment, and with the rising demand for AI processors, its products are becoming increasingly vital in semiconductor manufacturing, positioning the company for greater market share amidst China's push for semiconductor self-sufficiency.
See More
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Mirum Pharmaceuticals will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026, with a fireside chat at 1:10 p.m. ET, aimed at enhancing investor understanding of the company's strategic direction.
- Multiple Conference Engagements: The company will also attend The Citizens Life Sciences Conference and Barclays 28th Annual Global Healthcare Conference on March 10, 2026, showcasing its leadership in the rare disease sector and further enhancing investor interaction.
- Live Webcast Accessibility: All fireside chats will be webcast live via Mirum's corporate website, ensuring transparency of information and improving communication efficiency between the company and its investors.
- Product Portfolio and Pipeline: Mirum's commercial portfolio includes LIVMARLI® for Alagille syndrome and PFIC, along with CHOLBAM® for bile-acid synthesis disorders, demonstrating the company's deep expertise and market potential in rare disease treatments.
See More
